Literature DB >> 3116551

Double-blind study of Anandron versus placebo in stage D2 prostate cancer patients receiving buserelin. Results on 49 cases from a multicentre study.

H Navratil1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3116551

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN： 0361-7742


× No keyword cloud information.
  6 in total

Review 1.  [Problems and principles of hormone therapy of advanced prostate cancer].

Authors:  J E Altwein; P Faul
Journal:  Klin Wochenschr       Date:  1990-04-02

Review 2.  Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.

Authors:  C Mahler; J Verhelst; L Denis
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

Review 3.  Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.

Authors:  M G Harris; S G Coleman; D Faulds; P Chrisp
Journal:  Drugs Aging       Date:  1993 Jan-Feb       Impact factor: 3.923

4.  Pharmacokinetics of Anandron in patients with advanced carcinoma of the prostate.

Authors:  L Pendyala; P J Creaven; R Huben; D Tremblay; C Bertagna
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 5.  Second generation androgen receptor antagonists and challenges in prostate cancer treatment.

Authors:  Yanhua Chen; Qianqian Zhou; William Hankey; Xiaosheng Fang; Fuwen Yuan
Journal:  Cell Death Dis       Date:  2022-07-21       Impact factor: 9.685

6.  Maximal androgen blockade for the treatment of metastatic prostate cancer--a systematic review.

Authors:  H Lukka; T Waldron; L Klotz; E Winquist; J Trachtenberg
Journal:  Curr Oncol       Date:  2006-06       Impact factor: 3.677
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.